## Annex

# QUESTIONNAIRE FOR THE TESTING OF THE GUIDANCE ON RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

GENERAL INFORMATION ABOUT THE TESTING								
	☐ Party. Please specify: The Republic of Lithuania							
Q1. These results are being submitted on behalf of a:	Other Government. Please specify: <country's name=""></country's>							
	☐ Organization: Please specify: <organization's name=""></organization's>							
Q2. When was the testing of the Guidance conducted?	Please enter date: 2011-11-15							
Q3. Type of event where the testing of the Guidance was conducted?	Group event (e.g., workshop, training course, meeting). Please provide the title of the event and name of organizer: <type here=""></type>							
	Type of meeting:							
		Online						
		Individual exercise. Please provide your name, occupation and affiliation: dr. Vidmantas Bendokas, researcher, Institute of Horticulture, Lithuanian Research Centre for Agriculture and Forestry						
		Other: Plea	ase specify: <	Type here>				
Q4. Which sections of the Guidance were tested?	$\boxtimes$	□ Part I: The Roadmap for Risk assessment of LMOs						
	Part II: Specific types of LMOs or Traits:							
	☐ Risk assessment of LMOs with stacked genes or traits							
	☐ Risk assessment of LM crops with tolerance to abiotic stress							
		☐ Risk assessment of LM mosquitoes						
	O	VERALL I	EVALUATI(	ON				
			Very poor	Poor	Neutral	Good	Very good	
Please indicate the level of agreement you at	tribute	to each of ti	he questions	in the left co	<u>lumn.</u>			
Q5. How do you evaluate the level of consistency of the Guidance with the Cartagena Protocol on Biosafety, particularly with its Article 15 and Annex III?								
Q6. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs in a scientifically sound and case-by-case manner?						$\boxtimes$		
Q7. How do you evaluate the usefulness of the Guidance as a tool to assist countries in conducting and reviewing risk assessments of LMOs introduced into various receiving environments?						$\boxtimes$		

## PART I: ROADMAP FOR RISK ASSESSMENT OF LIVING MODIFIED ORGANISMS

Please answer each of the questions in the left column with "yes" or "no" and add comments if needed.					
Q8. Does the Roadmap provide useful guidance for conducting risk assessments of LMOs in accordance with the Protocol?	⊠ Yes □ No	Comments: <type here=""></type>			
Q9. Is the Roadmap useful to risk assessors who have limited experience with LMO risk assessment?	⊠ Yes □ No	Comments: <type here=""></type>			
Q10. Is the Roadmap organized in a logic and structured manner?	⊠ Yes □ No	Comments: <type here=""></type>			
Q11. Is the Roadmap user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	⊠ Yes □ No	Comments: <type here=""></type>			
Q12. Is the Roadmap applicable to all types of LMOs (e.g. plants, animals, microorganisms)?	⊠ Yes □ No	Comments: <type here=""></type>			
Q13. Is the Roadmap applicable to all types of introductions into the environment (e.g. small- and large-scale releases, placing on the market/commercialisation)?	⊠ Yes	Comments: <type here=""></type>			
Q14. Is there any other issue or concept that you would like to see included in the Roadmap?	☐ Yes ☑ No	Comments: <type here=""></type>			
Q15. Does the flowchart provide a useful graphic representation of the risk assessment process as described in the Roadmap?	⊠ Yes □ No	Comments: <type here=""></type>			

## PART II: SPECIFIC TYPES OF LIVING MODIFIED ORGANISMS OR TRAITS

## Risk assessment of living modified organisms with stacked genes or traits

		Ŭ				
Please answer each of the questions in the left column with "yes" or "no" and add comments if needed.						
Q16. Does this section provide useful guidance when conducting risk assessments of LMOs with stacked genes or traits in accordance with the Protocol?	⊠ Yes □ No	Comments: <type here=""></type>				
Q17. Is this section of the Guidance useful to risk assessors who have limited experience with risk assessments of LMOs with stacked genes of traits?	⊠ Yes □ No	Comments: <type here=""></type>				
Q18. Is this section of the Guidance organized in a logic and structured manner?	⊠ Yes □ No	Comments: <type here=""></type>				
Q19. Is this section of the Guidance user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	⊠ Yes □ No	Comments: <type here=""></type>				
Q20. Is there any other issue or concept that you would like to see included in this section of the Guidance?	☐ Yes	Comments: <type here=""></type>				
Risk assessment of living modified crops with tolerance to abiotic stress						
Please answer each of the questions in the left column with "yes" or "no" and add comments if needed.						
Q21. Does this section provide useful guidance when conducting risk assessments of LM crops with tolerance to abiotic stress(es) in accordance with the Protocol?	⊠ Yes □ No	Comments: <type here=""></type>				
Q22. Is this section of the Guidance useful to risk assessors who have limited experience with risk assessments of LM crops with tolerance to abiotic stress(es)?	⊠ Yes □ No	Comments: <type here=""></type>				
Q23. Is this section of the Guidance organized in a logic and structured manner?	⊠ Yes □ No	Comments: <type here=""></type>				
Q24. Is this section of the Guidance user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	⊠ Yes □ No	Comments: <type here=""></type>				
Q25. Is there any other issue or concept that you would like to see included in this section of the Guidance?	☐ Yes	Comments: <type here=""></type>				

Risk assessment of living modified mosquitoes						
Please answer each of the questions in the left column with "yes" or "no" and add comments if needed.						
Q26. Does this section provide useful guidance when conducting risk assessments of LM mosquitoes in accordance with the Protocol?	⊠ Yes	Comments: <type here=""></type>				
Q27. Is this section of the Guidance useful to risk assessors who have limited experience with risk assessments of LM mosquitoes?	⊠ Yes	Comments: <type here=""></type>				
Q28. Is this section of the Guidance organized in a logic and structured manner?	⊠ Yes	Comments: <type here=""></type>				
Q29. Is this section of the Guidance user-friendly taking into account that risk assessment is a complex scientific and multidisciplinary activity?	⊠ Yes □ No	Comments: <type here=""></type>				
Q30. Is there any other issue or concept that you would like to see included in this section of the Guidance?	☐ Yes ⊠ No	Comments: <type here=""></type>				

#### ADDITIONAL COMMENTS

Please add any additional comment you may have regarding the "Guidance on Risk Assessment of Living Modified Organisms" below.

Q31. These criteria are properly projected and correspond to Cartagena Protocol on Biosafety and Annex III of this Protocol. No field trials are performed in Lithuania; as a result, no practical experience is gained in this area and just the theoretical estimation is provided for the guidance above.

----